首页 > 最新文献

Therapeutic Apheresis and Dialysis最新文献

英文 中文
Updated evidence of beneficial effect of LDL apheresis for refractory nephrotic syndrome due to a variety of causative diseases for nationwide and global approval. 低密度脂蛋白单采治疗因多种病因引起的难治性肾病综合征有益效果的最新证据已在全国和全球获得批准。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2023-12-01 Epub Date: 2023-08-18 DOI: 10.1111/1744-9987.14056
Eri Muso, Hiroko Kakita, Hiroyuki Suzuki, Tatsuo Tsukamoto

Low-density lipoprotein apheresis (LDL-A) therapy has shown reasonable efficacy in treating nephrotic syndrome (NS) refractory to initial drug therapy and has been covered by National Health Insurance for the indication of drug-resistant focal segmental glomerulosclerosis (FSGS) since 1992 in Japan and has contributed to liberating substantial number of patients of this disease from entering into end-stage renal disease by easier practical application in actual clinical settings. Subsequently, various beneficial evidence of this treatment has accumulated on those other than FSGS, however, due to the limitation of covered disease insurance only for FSGS, patients with diseases other than FSGS are unlikely to benefit from this treatment in practice. This review summarizes the therapeutic evidence of the beneficial effect of LDL-A accumulated to date and the mechanisms of action analyzed from multifaceted perspectives. examines the applicability of expanding insurance coverage for diseases other than FSGS.

低密度脂蛋白单采(LDL-A)疗法在治疗最初药物治疗难治的肾病综合征(NS)方面显示出合理的疗效,自1992年以来,日本已将其纳入国家健康保险的耐药局灶节段性肾小球硬化症(FSGS)指征范围,并有助于使大量肾病患者免于进入终末期肾脏疾病更容易在实际临床环境中实际应用。随后,在FSGS以外的患者身上积累了这种治疗的各种有益证据,然而,由于仅针对FSGS的承保疾病保险的限制,FSGS以外疾病的患者在实践中不太可能从这种治疗中受益。这篇综述总结了迄今为止积累的LDL-A有益作用的治疗证据,以及从多方面分析的作用机制。审查扩大FSGS以外疾病保险范围的适用性。
{"title":"Updated evidence of beneficial effect of LDL apheresis for refractory nephrotic syndrome due to a variety of causative diseases for nationwide and global approval.","authors":"Eri Muso,&nbsp;Hiroko Kakita,&nbsp;Hiroyuki Suzuki,&nbsp;Tatsuo Tsukamoto","doi":"10.1111/1744-9987.14056","DOIUrl":"10.1111/1744-9987.14056","url":null,"abstract":"<p><p>Low-density lipoprotein apheresis (LDL-A) therapy has shown reasonable efficacy in treating nephrotic syndrome (NS) refractory to initial drug therapy and has been covered by National Health Insurance for the indication of drug-resistant focal segmental glomerulosclerosis (FSGS) since 1992 in Japan and has contributed to liberating substantial number of patients of this disease from entering into end-stage renal disease by easier practical application in actual clinical settings. Subsequently, various beneficial evidence of this treatment has accumulated on those other than FSGS, however, due to the limitation of covered disease insurance only for FSGS, patients with diseases other than FSGS are unlikely to benefit from this treatment in practice. This review summarizes the therapeutic evidence of the beneficial effect of LDL-A accumulated to date and the mechanisms of action analyzed from multifaceted perspectives. examines the applicability of expanding insurance coverage for diseases other than FSGS.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":" ","pages":"987-999"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10012270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short term-efficacy and tolerability of Rheocarna, a novel direct hemoperfusion adsorptive column, for chronic limb-threatening ischemia in dialysis patients: A single-center case series. Rheocarna,一种新型直接血液灌流吸附柱,治疗透析患者慢性肢体威胁性缺血的短期疗效和耐受性:一个单中心病例系列。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2023-12-01 Epub Date: 2023-08-21 DOI: 10.1111/1744-9987.14049
Eri Imai, Shuzo Kaneko, Ainori Hoshimoto, Rina Hisada, Makiko Harano, Emi Anno, So Hagiwara, Shunsuke Ozaki, Hiroko Torii, Yusuke Tsukamoto

Introduction: With population aging and lifestyle changes, the number of patients with chronic limb-threatening ischemia (CLTI) is increasing, and refractory or recurrent lesions are more common, especially in chronic dialysis patients. In March 2021, a new type of adsorptive cellulose bead column immobilized with dextran sulfate and L-tryptophan for direct hemoperfusion (DHP) was approved by Japan's medical insurance system as a treatment for CLTI.

Methods: We retrospectively analyzed 17 cases of CLTI in dialysis patients treated with DHP using the novel column (Rheocarna) (DHP-R) at our hospital from May 2021 to October 2022. The short-term of efficacy of DHP-R was judged qualitatively by the foot care team every 2 weeks based on the assessment of skin color, warmth, ulcer epithelialization or shrinkage of the ulcer area, and foot pain. The final judgment of efficacy was made after the final DHP-R session.

Results: The median age of patients was 66 years, the median dialysis duration was 10 years, 15 cases (88%) were male, and 15 cases (88%) had diabetes. The median total number of sessions was eight. In comparing the groups in which DHP-R was effective and ineffective, there was no significant difference in any factors including patient background data (i.e., age, diabetes, low-density lipoprotein cholesterol, hemoglobin, dialysis duration, etc.), type of anticoagulants, and presence of episodes of blood pressure drop or circuit clotting during session. Three cases with symptomatic hypotension during the session and two cases with circuit clotting that did not improve with increased heparin dose all resolved immediately after changing the anticoagulant from heparin to nafamostat mesylate (NM).

Conclusion: Identification of patients' characteristics in which DHP-R is favorable and some reliable index that allow a rapid decision to continue DHP-R are needed. In addition, validating whether the use of NM as anticoagulant affects the efficacy of DHP-R for CTLI treatment remains a challenge to resolve.

引言:随着人口老龄化和生活方式的改变,慢性肢体威胁性缺血(CLTI)患者数量不断增加,难治性或复发性病变更为常见,尤其是在慢性透析患者中。2021年3月,一种新型的用葡聚糖硫酸酯和L-色氨酸固定的吸附性纤维素珠柱被日本医疗保险系统批准作为CLTI的治疗方法,用于直接血液灌流(DHP)。方法:我们回顾性分析了2021年5月至2022年10月在我院使用新型柱(Rheocarna)(DHP-R)接受DHP治疗的透析患者中的17例CLTI。足部护理团队每2个月对DHP-R的短期疗效进行定性判断 周,根据皮肤颜色、温度、溃疡上皮化或溃疡面积缩小以及足部疼痛的评估。疗效的最终判断是在最后一次DHP-R治疗后做出的。结果:患者的中位年龄为66岁 年,中位透析时间为10 年,男性15例(88%),糖尿病15例(88%)。会话总数的中位数为8次。在比较DHP-R有效和无效的组时,包括患者背景数据(即年龄、糖尿病、低密度脂蛋白胆固醇、血红蛋白、透析持续时间等)、抗凝血剂类型以及治疗期间是否出现血压下降或回路凝血在内的任何因素均无显著差异。三例在治疗期间出现症状性低血压的病例和两例在增加肝素剂量后没有改善的回路凝血病例,在将抗凝剂从肝素改为甲磺酸那法莫司他(NM)后立即缓解。结论:需要确定DHP-R有利的患者特征和一些可靠的指标,以便快速决定是否继续DHP-R。此外,验证NM作为抗凝剂的使用是否会影响DHP-R治疗CTLI的疗效仍然是一个有待解决的挑战。
{"title":"Short term-efficacy and tolerability of Rheocarna, a novel direct hemoperfusion adsorptive column, for chronic limb-threatening ischemia in dialysis patients: A single-center case series.","authors":"Eri Imai,&nbsp;Shuzo Kaneko,&nbsp;Ainori Hoshimoto,&nbsp;Rina Hisada,&nbsp;Makiko Harano,&nbsp;Emi Anno,&nbsp;So Hagiwara,&nbsp;Shunsuke Ozaki,&nbsp;Hiroko Torii,&nbsp;Yusuke Tsukamoto","doi":"10.1111/1744-9987.14049","DOIUrl":"10.1111/1744-9987.14049","url":null,"abstract":"<p><strong>Introduction: </strong>With population aging and lifestyle changes, the number of patients with chronic limb-threatening ischemia (CLTI) is increasing, and refractory or recurrent lesions are more common, especially in chronic dialysis patients. In March 2021, a new type of adsorptive cellulose bead column immobilized with dextran sulfate and L-tryptophan for direct hemoperfusion (DHP) was approved by Japan's medical insurance system as a treatment for CLTI.</p><p><strong>Methods: </strong>We retrospectively analyzed 17 cases of CLTI in dialysis patients treated with DHP using the novel column (Rheocarna) (DHP-R) at our hospital from May 2021 to October 2022. The short-term of efficacy of DHP-R was judged qualitatively by the foot care team every 2 weeks based on the assessment of skin color, warmth, ulcer epithelialization or shrinkage of the ulcer area, and foot pain. The final judgment of efficacy was made after the final DHP-R session.</p><p><strong>Results: </strong>The median age of patients was 66 years, the median dialysis duration was 10 years, 15 cases (88%) were male, and 15 cases (88%) had diabetes. The median total number of sessions was eight. In comparing the groups in which DHP-R was effective and ineffective, there was no significant difference in any factors including patient background data (i.e., age, diabetes, low-density lipoprotein cholesterol, hemoglobin, dialysis duration, etc.), type of anticoagulants, and presence of episodes of blood pressure drop or circuit clotting during session. Three cases with symptomatic hypotension during the session and two cases with circuit clotting that did not improve with increased heparin dose all resolved immediately after changing the anticoagulant from heparin to nafamostat mesylate (NM).</p><p><strong>Conclusion: </strong>Identification of patients' characteristics in which DHP-R is favorable and some reliable index that allow a rapid decision to continue DHP-R are needed. In addition, validating whether the use of NM as anticoagulant affects the efficacy of DHP-R for CTLI treatment remains a challenge to resolve.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":" ","pages":"1010-1016"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10030051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is photopheresis? Role of extracorporeal photopheresis in the treatment of GvHD and its practice in Sweden. 什么是照相术?体外光疗法在GvHD治疗中的作用及其在瑞典的实践。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2023-12-01 Epub Date: 2023-09-10 DOI: 10.1111/1744-9987.14051
Yoshimi Fukumaki Karlsson, Gösta Berlin
{"title":"What is photopheresis? Role of extracorporeal photopheresis in the treatment of GvHD and its practice in Sweden.","authors":"Yoshimi Fukumaki Karlsson, Gösta Berlin","doi":"10.1111/1744-9987.14051","DOIUrl":"10.1111/1744-9987.14051","url":null,"abstract":"","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":" ","pages":"1051-1052"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10203113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of sodium thiosulfate on serum calcification factors in patients undergoing maintenance hemodialysis. 硫代硫酸钠对维持性血液透析患者血清钙化因子的影响。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2023-12-01 Epub Date: 2023-07-09 DOI: 10.1111/1744-9987.14029
Pan Liu, Xiang Xu, YuFu Wang, XiaoNa Long, XunJia Li, HongYing Peng

Objective: To investigate the effect of sodium thiosulfate (STS) on serum calcification factors in patients undergoing maintenance hemodialysis.

Methods: Forty-four Patients were randomly divided into control group (n = 22) and observation group (n = 22) by envelope method (block 4 randomization). The control group received routine treatment while observation group was treated with STS on the basis of routine treatment. The biochemical indicators, including BUN, UA, SCr, Ca2+ , P3- , calcium-phosphorus product, PTH, hs-CRP, TG, TC, HDL, LDL, and serum calcification factor MGP, FA, FGF-23, and OPG levels were compared before and after treatment.

Results: Control group had no statistically significant difference in the levels of vascular calcification factors MGP, FA, FGF-23, and OPG before and after treatment (p > 0.05). Whereas observation group had higher levels of MGP and FA, and lower levels of FGF-23 and OPG after treatment than before treatment (p < 0.05). The levels of MGP and FA in observation group were higher than those in control group, and FGF-23 and OPG were lower than those in control group (p < 0.05).

Conclusion: It is speculated that sodium thiosulfate can alleviate the progression of vascular calcification by changing the levels of calcification factors.

目的:探讨硫代硫酸钠(STS)对维持性血液透析患者血清钙化因子的影响。方法:将44例患者随机分为对照组(n = 22)和观察组(n = 22)(块4随机化)。对照组采用常规治疗,观察组在常规治疗的基础上采用STS治疗。比较治疗前后的生化指标,包括BUN、UA、SCr、Ca2+、P3-、钙磷产物、PTH、hs-CRP、TG、TC、HDL、LDL以及血清钙化因子MGP、FA、FGF-23和OPG水平。结果:对照组治疗前后血管钙化因子MGP、FA、FGF-23、OPG水平差异无统计学意义(p > 观察组治疗后MGP和FA水平高于治疗前,FGF-23和OPG水平低于治疗前(p 结论:硫代硫酸钠可以通过改变钙化因子的水平来减轻血管钙化的进展。
{"title":"Effects of sodium thiosulfate on serum calcification factors in patients undergoing maintenance hemodialysis.","authors":"Pan Liu,&nbsp;Xiang Xu,&nbsp;YuFu Wang,&nbsp;XiaoNa Long,&nbsp;XunJia Li,&nbsp;HongYing Peng","doi":"10.1111/1744-9987.14029","DOIUrl":"10.1111/1744-9987.14029","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of sodium thiosulfate (STS) on serum calcification factors in patients undergoing maintenance hemodialysis.</p><p><strong>Methods: </strong>Forty-four Patients were randomly divided into control group (n = 22) and observation group (n = 22) by envelope method (block 4 randomization). The control group received routine treatment while observation group was treated with STS on the basis of routine treatment. The biochemical indicators, including BUN, UA, SCr, Ca<sup>2+</sup> , P<sup>3-</sup> , calcium-phosphorus product, PTH, hs-CRP, TG, TC, HDL, LDL, and serum calcification factor MGP, FA, FGF-23, and OPG levels were compared before and after treatment.</p><p><strong>Results: </strong>Control group had no statistically significant difference in the levels of vascular calcification factors MGP, FA, FGF-23, and OPG before and after treatment (p > 0.05). Whereas observation group had higher levels of MGP and FA, and lower levels of FGF-23 and OPG after treatment than before treatment (p < 0.05). The levels of MGP and FA in observation group were higher than those in control group, and FGF-23 and OPG were lower than those in control group (p < 0.05).</p><p><strong>Conclusion: </strong>It is speculated that sodium thiosulfate can alleviate the progression of vascular calcification by changing the levels of calcification factors.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":" ","pages":"1079-1087"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9761086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effects of N-acetyl-L-tryptophan on desorption of the protein-bound uremic toxin indoxyl sulfate and effects on uremic sarcopenia. N-乙酰-L-色氨酸对蛋白结合的尿毒症毒素硫酸吲哚酚解吸的影响以及对尿毒症少肌症的影响。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2023-12-01 Epub Date: 2023-08-19 DOI: 10.1111/1744-9987.14047
Atsushi Ohashi, Masashi Nakatani, Hideo Hori, Shigeru Nakai, Kunihiro Tsuchida, Midori Hasegawa, Naotake Tsuboi

Introduction: Indoxyl sulfate (IS) is a protein-bound uremic toxin that causes uremic sarcopenia. IS has poor dialysis clearance; however, the addition of a binding competitor improves its removal efficiency.

Methods: Dialysis experiments were performed using N-acetyl-l-tryptophan (L-NAT) instead of l-tryptophan (Trp) using pooled sera obtained from dialysis patients. The molecular structures of L-NAT and Trp were similar to that of IS. Therefore, we examined whether Trp and L-NAT were involved in muscle atrophy in the same manner as IS by performing culture experiments using a human myotube cell line.

Results: The removal efficiency of L-NAT was the same as that of Trp. However, L-NAT concentrations in the pooled sera increased at the end of the experiment. Trp (1 mM) decreased the area of human myocytes, similar to IS, whereas L-NAT did not.

Conclusion: L-NAT is a binding competitor with the ability to remove protein-bound IS while preventing sarcopenia.

引言:硫酸吲哚酚(IS)是一种与蛋白质结合的尿毒症毒素,可导致尿毒症少肌症。IS透析清除率低;然而,添加结合竞争对手提高了其去除效率。方法:使用从透析患者获得的混合血清,使用N-乙酰-l-色氨酸(l-NAT)代替l-色氨酸进行透析实验。L-NAT和Trp的分子结构与IS相似。因此,我们通过使用人肌管细胞系进行培养实验来检测Trp和L-NAT是否以与IS相同的方式参与肌肉萎缩。结果:L-NAT的去除效率与Trp的去除效率相同,但在实验结束时,合并血清中的L-NAT浓度增加。Trp(1 mM)降低了人肌细胞的面积,类似于IS,而L-NAT没有。结论:L-NAT是一种结合竞争对手,能够去除蛋白结合的is,同时预防少肌症。
{"title":"Effects of N-acetyl-L-tryptophan on desorption of the protein-bound uremic toxin indoxyl sulfate and effects on uremic sarcopenia.","authors":"Atsushi Ohashi,&nbsp;Masashi Nakatani,&nbsp;Hideo Hori,&nbsp;Shigeru Nakai,&nbsp;Kunihiro Tsuchida,&nbsp;Midori Hasegawa,&nbsp;Naotake Tsuboi","doi":"10.1111/1744-9987.14047","DOIUrl":"10.1111/1744-9987.14047","url":null,"abstract":"<p><strong>Introduction: </strong>Indoxyl sulfate (IS) is a protein-bound uremic toxin that causes uremic sarcopenia. IS has poor dialysis clearance; however, the addition of a binding competitor improves its removal efficiency.</p><p><strong>Methods: </strong>Dialysis experiments were performed using N-acetyl-l-tryptophan (L-NAT) instead of l-tryptophan (Trp) using pooled sera obtained from dialysis patients. The molecular structures of L-NAT and Trp were similar to that of IS. Therefore, we examined whether Trp and L-NAT were involved in muscle atrophy in the same manner as IS by performing culture experiments using a human myotube cell line.</p><p><strong>Results: </strong>The removal efficiency of L-NAT was the same as that of Trp. However, L-NAT concentrations in the pooled sera increased at the end of the experiment. Trp (1 mM) decreased the area of human myocytes, similar to IS, whereas L-NAT did not.</p><p><strong>Conclusion: </strong>L-NAT is a binding competitor with the ability to remove protein-bound IS while preventing sarcopenia.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":" ","pages":"1023-1027"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10029034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experience with pre-diluted plasma exchange therapy for hyperviscosity syndrome. 预稀释血浆置换治疗高粘滞综合征的经验。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2023-12-01 Epub Date: 2023-08-21 DOI: 10.1111/1744-9987.14053
Shigeyuki Igarashi, Yasutaka Kamikawa, Syuji Ono, Gakuya Maekawa, Hiroyuki Kishigami, Kazuki Kawamura, Takumi Oonogi, Toshihiko Nagano

Introduction: Plasma exchange therapy (PE) is useful for patients with primary macroglobulinemia and multiple myeloma who present with hyperviscosity syndrome. However, hyperviscous blood may coagulate in the circuit during treatment, and in that case necessitate discontinuation of the treatment. This time, we report that we were able to prevent coagulation in the circuit by adding some ideas during the membrane separation method.

Methods: Physiological saline is injected in front of the plasma separation membrane to pre-dilute the blood, followed by filtration through the plasma separation membrane.

Results: As a result of pre-diluting with physiological saline to reduce the viscosity entering the separation membrane, it was possible to process the planned target amount.

Conclusion: In patients with hyperviscosity syndrome who showed intracircuit coagulation during plasma exchange therapy, devising a predilution method should be considered as one of the ways to continue treatment.

引言:血浆置换疗法(PE)适用于原发性巨球蛋白血症和多发性骨髓瘤伴高粘滞综合征的患者。然而,在治疗过程中,高粘度血液可能会在回路中凝结,在这种情况下,需要停止治疗。这一次,我们报告说,我们能够通过在膜分离方法中添加一些想法来防止回路中的凝结。方法:在血浆分离膜前注入生理盐水预稀释血液,然后通过血浆分离膜过滤。结果:由于用生理盐水预稀释以降低进入分离膜的粘度,因此可以处理计划的目标量。结论:对于在血浆置换治疗过程中出现回路内凝血的高粘度综合征患者,应考虑设计预溶解方法作为继续治疗的方法之一。
{"title":"Experience with pre-diluted plasma exchange therapy for hyperviscosity syndrome.","authors":"Shigeyuki Igarashi,&nbsp;Yasutaka Kamikawa,&nbsp;Syuji Ono,&nbsp;Gakuya Maekawa,&nbsp;Hiroyuki Kishigami,&nbsp;Kazuki Kawamura,&nbsp;Takumi Oonogi,&nbsp;Toshihiko Nagano","doi":"10.1111/1744-9987.14053","DOIUrl":"10.1111/1744-9987.14053","url":null,"abstract":"<p><strong>Introduction: </strong>Plasma exchange therapy (PE) is useful for patients with primary macroglobulinemia and multiple myeloma who present with hyperviscosity syndrome. However, hyperviscous blood may coagulate in the circuit during treatment, and in that case necessitate discontinuation of the treatment. This time, we report that we were able to prevent coagulation in the circuit by adding some ideas during the membrane separation method.</p><p><strong>Methods: </strong>Physiological saline is injected in front of the plasma separation membrane to pre-dilute the blood, followed by filtration through the plasma separation membrane.</p><p><strong>Results: </strong>As a result of pre-diluting with physiological saline to reduce the viscosity entering the separation membrane, it was possible to process the planned target amount.</p><p><strong>Conclusion: </strong>In patients with hyperviscosity syndrome who showed intracircuit coagulation during plasma exchange therapy, devising a predilution method should be considered as one of the ways to continue treatment.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":" ","pages":"1035-1039"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10040026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determination of anxiety, depression, avoidance and obsessions experienced by hemodialysis patients during the COVID-19. 新冠肺炎期间血液透析患者经历的焦虑、抑郁、回避和强迫的测定。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2023-12-01 Epub Date: 2023-06-29 DOI: 10.1111/1744-9987.14031
Nazlı Koşunalp, Mehtap Kavurmaci

Introduction: The purpose of this study was to ascertain the levels of anxiety, despair, avoidance, and obsessions that hemodialysis patients dealt with during the pandemic.

Methods: The study was conducted with 139 hemodialysis patients. Research data "Coronavirus Anxiety Scale (CAS)," "Hospital Anxiety and Depression Scale (HAD)," "COVID-19 Avoidance Scale" (AA-COVID-19) and "Coronavirus Obsession Scale (OCS)." The data obtained from the research were analyzed using the SPSS 21 package program.

Results: The average score of the patients on the CAS scale was 0.73 ± 1.17, on the HAD-A scale was 5.94 ± 3.67, and on the HAD-D scale was 7.06 ± 3.89. The COVID-19 outbreak has consequently had a severe impact on hemodialysis patients' mental health.

Conclusion: Covid 19 epidemic, the health sector failed to protect the mental health of patients. However, new epidemics and disasters await the world in the future. In these results show that new strategies need to be developed.

引言:本研究的目的是确定血液透析患者在疫情期间的焦虑、绝望、回避和痴迷程度。方法:对139例血液透析患者进行研究。研究数据“冠状病毒焦虑量表(CAS)”、“医院焦虑和抑郁量表(HAD)”、《新冠肺炎回避量表》(AA-CVID-19)和《冠状病毒困扰量表(OCS)》。结果:患者在CAS量表上的平均得分为0.73 ± 1.17,HAD-A评分为5.94 ± 3.67,HAD-D量表为7.06 ± 3.89.新冠肺炎疫情因此对血液透析患者的心理健康产生了严重影响。结论:新冠肺炎疫情19日,卫生部门未能保护患者的心理健康。然而,新的流行病和灾难在未来等待着世界。这些结果表明,需要制定新的战略。
{"title":"Determination of anxiety, depression, avoidance and obsessions experienced by hemodialysis patients during the COVID-19.","authors":"Nazlı Koşunalp,&nbsp;Mehtap Kavurmaci","doi":"10.1111/1744-9987.14031","DOIUrl":"10.1111/1744-9987.14031","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to ascertain the levels of anxiety, despair, avoidance, and obsessions that hemodialysis patients dealt with during the pandemic.</p><p><strong>Methods: </strong>The study was conducted with 139 hemodialysis patients. Research data \"Coronavirus Anxiety Scale (CAS),\" \"Hospital Anxiety and Depression Scale (HAD),\" \"COVID-19 Avoidance Scale\" (AA-COVID-19) and \"Coronavirus Obsession Scale (OCS).\" The data obtained from the research were analyzed using the SPSS 21 package program.</p><p><strong>Results: </strong>The average score of the patients on the CAS scale was 0.73 ± 1.17, on the HAD-A scale was 5.94 ± 3.67, and on the HAD-D scale was 7.06 ± 3.89. The COVID-19 outbreak has consequently had a severe impact on hemodialysis patients' mental health.</p><p><strong>Conclusion: </strong>Covid 19 epidemic, the health sector failed to protect the mental health of patients. However, new epidemics and disasters await the world in the future. In these results show that new strategies need to be developed.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":" ","pages":"1070-1078"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10055506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 43rd Annual Meeting of the Japanese Society for Apheresis. 第43届日本单采术学会年会。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2023-12-01 Epub Date: 2023-08-17 DOI: 10.1111/1744-9987.14055
Takashi Wada
{"title":"The 43rd Annual Meeting of the Japanese Society for Apheresis.","authors":"Takashi Wada","doi":"10.1111/1744-9987.14055","DOIUrl":"10.1111/1744-9987.14055","url":null,"abstract":"","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":" ","pages":"985-986"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10396727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medullary Thyroid Carcinoma: A Single Institute Experience. 甲状腺髓样癌:单一研究所的经验。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2023-12-01 Epub Date: 2023-05-22 DOI: 10.1007/s12070-023-03867-2
Sonal Trivedi, T Salahuddin, Mohamed Taher Mithi, Priyank Rathod, Arpit Bandi, Shashank J Pandya, Mohit Sharma, Shailesh Patel, Vikas Warikoo, Ketul Puj, Abhijeet Salunkhe, Keval Patel, Shivam Pandya

Medullary thyroid carcinoma is a rare tumour that is anatomically located in the thyroid gland but is functionally a neuroendocrine tumour. It is usually a disease of older age group but manifests in a young patient in familial form. It is derived from parafollicular c cells and has a predilection for lymph node metastasis. It is associated with slow growth in thyroid gland with early nodal metastasis. Serum calcitonin is useful as a preoperative marker of disease burden and prognosis. In the preoperative period serum levels of calcitonin can guide regarding the need for compartment wise lymph node dissection and the possibility of distant metastasis. It is used as a tool of surveillance in the postoperative period. The levels of serum CEA and calcitonin and their doubling time is a useful guide in the detection of early recurrence or distant metastasis. Imaging modality useful for diagnosis is USG in a majority of patients. Thus, the initial diagnosis and preoperative assessment of medullary thyroid carcinoma is similar to other forms of thyroid cancer but further management of disease differs significantly form other forms of differentiated thyroid carcinoma or even anaplastic carcinoma. Prognosis however differs according to age, gender, presence or absence of lymph node metastasis at presentation, metastatic disease at presentation and levels of biochemical markers.

甲状腺髓样癌是一种罕见的肿瘤,解剖上位于甲状腺,但功能上是一种神经内分泌肿瘤。它通常是一种老年群体的疾病,但在家族形式的年轻患者中表现出来。它来源于滤泡旁c细胞,有淋巴结转移的倾向。它与甲状腺生长缓慢和早期淋巴结转移有关。血清降钙素可作为术前疾病负担和预后的指标。术前血清降钙素水平可以指导是否需要隔室淋巴结清扫和远处转移的可能性。它被用作术后监测的工具。血清CEA和降钙素水平及其倍增时间对早期复发或远处转移的诊断有重要指导意义。超声心动图对大多数患者的诊断有用。因此,甲状腺髓样癌的初始诊断和术前评估与其他形式的甲状腺癌相似,但进一步的疾病处理与其他形式的分化型甲状腺癌甚至间变性癌有明显不同。然而,预后因年龄、性别、出现时是否有淋巴结转移、出现时是否有转移性疾病以及生化标志物水平而异。
{"title":"Medullary Thyroid Carcinoma: A Single Institute Experience.","authors":"Sonal Trivedi, T Salahuddin, Mohamed Taher Mithi, Priyank Rathod, Arpit Bandi, Shashank J Pandya, Mohit Sharma, Shailesh Patel, Vikas Warikoo, Ketul Puj, Abhijeet Salunkhe, Keval Patel, Shivam Pandya","doi":"10.1007/s12070-023-03867-2","DOIUrl":"10.1007/s12070-023-03867-2","url":null,"abstract":"<p><p>Medullary thyroid carcinoma is a rare tumour that is anatomically located in the thyroid gland but is functionally a neuroendocrine tumour. It is usually a disease of older age group but manifests in a young patient in familial form. It is derived from parafollicular c cells and has a predilection for lymph node metastasis. It is associated with slow growth in thyroid gland with early nodal metastasis. Serum calcitonin is useful as a preoperative marker of disease burden and prognosis. In the preoperative period serum levels of calcitonin can guide regarding the need for compartment wise lymph node dissection and the possibility of distant metastasis. It is used as a tool of surveillance in the postoperative period. The levels of serum CEA and calcitonin and their doubling time is a useful guide in the detection of early recurrence or distant metastasis. Imaging modality useful for diagnosis is USG in a majority of patients. Thus, the initial diagnosis and preoperative assessment of medullary thyroid carcinoma is similar to other forms of thyroid cancer but further management of disease differs significantly form other forms of differentiated thyroid carcinoma or even anaplastic carcinoma. Prognosis however differs according to age, gender, presence or absence of lymph node metastasis at presentation, metastatic disease at presentation and levels of biochemical markers.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"8 1","pages":"2884-2889"},"PeriodicalIF":1.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85155607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Apheresis and Dialysis Forthcoming Events December 2023 治疗性采血和透析即将举行的活动2023年12月
4区 医学 Q3 HEMATOLOGY Pub Date : 2023-11-02 DOI: 10.1111/1744-9987.13882
Therapeutic Apheresis and DialysisVolume 27, Issue 6 p. 1130-1130 FORTHCOMING EVENTS Therapeutic Apheresis and Dialysis Forthcoming Events December 2023 First published: 02 November 2023 https://doi.org/10.1111/1744-9987.13882Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume27, Issue6December 2023Pages 1130-1130 RelatedInformation
治疗单采和透析第27卷第6期1130-1130即将发生的事件治疗单采和透析即将发生的事件2023年12月首次出版:2023年11月2日https://doi.org/10.1111/1744-9987.13882Read全文taboutpdf ToolsRequest permissionExport citation添加到favoritesTrack citation ShareShare给予accessShare全文accessShare全文accessShare全文accessShare全文accessShare请查看我们的使用条款和条件,并勾选下面的复选框以分享文章的全文版本。我已经阅读并接受了Wiley在线图书馆使用共享链接的条款和条件,请使用下面的链接与您的朋友和同事分享本文的全文版本。学习更多的知识。复制URL共享链接共享一个emailfacebooktwitterlinkedinreddit微信本文无摘要vol . 27, Issue6December 2023Pages 1130-1130
{"title":"<i>Therapeutic Apheresis and Dialysis</i> Forthcoming Events December 2023","authors":"","doi":"10.1111/1744-9987.13882","DOIUrl":"https://doi.org/10.1111/1744-9987.13882","url":null,"abstract":"Therapeutic Apheresis and DialysisVolume 27, Issue 6 p. 1130-1130 FORTHCOMING EVENTS Therapeutic Apheresis and Dialysis Forthcoming Events December 2023 First published: 02 November 2023 https://doi.org/10.1111/1744-9987.13882Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume27, Issue6December 2023Pages 1130-1130 RelatedInformation","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"30 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135973490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutic Apheresis and Dialysis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1